+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 4
Age: 18Years - 75Years
All Genders
ID06317805

Randomized Study Comparing Initial Triple Therapy Including Parenteral Treprostinil Versus Double Oral Therapy in Adults with Pulmonary Arterial Hypertension

Led by AOP Orphan Pharmaceuticals AG · Updated on 2026-10-29

110

Participants Needed

28

Research Sites

4 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are investigating the effectiveness of initial triple combination therapy versus initial double oral therapy in adults with pulmonary arterial hypertension PAH who are either intermediate-high risk or intermediate-low risk with severe hemodynamic impairment. This phase IV, randomized, open-label trial aims to optimize treatment strategies for PAH by comparing the proportion of patients achieving low-risk status between the two treatments. The study focuses on patients with idiopathic, hereditary, drug-induced, connective tissue disease-associated, or corrected congenital heart disease-related PAH. Participants are randomly assigned to one of two groups one receives double oral therapy consisting of an endothelin receptor antagonist ERA and a phosphodiesterase type-5 inhibitor PDE-5i, while the other group receives initial triple therapy that includes the same double oral combination plus parenteral treprostinil administered subcutaneously or intravenously via an infusion pump. All medications start within three weeks of randomization, and patients in the treprostinil group receive training on pump use and medication management. Dose adjustments of treprostinil are made to reach a target or maximum tolerated dose over 24 weeks and beyond. Participants will be followed for 12 to 48 weeks with up to 10 visits, including phone calls and in-person assessments. The study evaluates risk status using a standardized four-strata risk-assessment tool, hemodynamic parameters via right heart catheterization, echocardiogram measures, and patient-reported outcomes such as quality of life and symptom questionnaires. Safety is monitored through routine care without additional invasive procedures beyond standard PAH management. The primary outcome is the achievement of low-risk status between weeks 12 and 48, with secondary outcomes assessing heart function, clinical worsening, survival, and quality of life changes.

CONDITIONS

Brief Title

Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients

Research Team

C

Clinical Project Manager

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here